Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2022 | 1 |
2023 | 6 |
2024 | 0 |
Search Results
7 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis.
N Engl J Med. 2023 Jun 29;388(26):2444-2455. doi: 10.1056/NEJMoa2207940.
N Engl J Med. 2023.
PMID: 37379135
Clinical Trial.
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial.
Sands BE, Irving PM, Hoops T, Izanec JL, Gao LL, Gasink C, Greenspan A, Allez M, Danese S, Hanauer SB, Jairath V, Kuehbacher T, Lewis JD, Loftus EV Jr, Mihaly E, Panaccione R, Scherl E, Shchukina OB, Sandborn WJ; SEAVUE Study Group.
Sands BE, et al.
Lancet. 2022 Jun 11;399(10342):2200-2211. doi: 10.1016/S0140-6736(22)00688-2.
Lancet. 2022.
PMID: 35691323
Clinical Trial.
Item in Clipboard
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial.
Feagan BG, Sands BE, Sandborn WJ, Germinaro M, Vetter M, Shao J, Sheng S, Johanns J, Panés J; VEGA Study Group.
Feagan BG, et al.
Lancet Gastroenterol Hepatol. 2023 Apr;8(4):307-320. doi: 10.1016/S2468-1253(22)00427-7. Epub 2023 Feb 1.
Lancet Gastroenterol Hepatol. 2023.
PMID: 36738762
Clinical Trial.
Item in Clipboard
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study.
Peyrin-Biroulet L, Allegretti JR, Rubin DT, Bressler B, Germinaro M, Huang KG, Shipitofsky N, Zhang H, Wilson R, Han C, Feagan BG, Sandborn WJ, Panés J, Hisamatsu T, Lichtenstein GR, Sands BE, Dignass A; QUASAR Study Group.
Peyrin-Biroulet L, et al.
Gastroenterology. 2023 Dec;165(6):1443-1457. doi: 10.1053/j.gastro.2023.08.038. Epub 2023 Sep 1.
Gastroenterology. 2023.
PMID: 37659673
Free article.
Clinical Trial.
Item in Clipboard
Economic Burden of Cervical Cancer in Bulgaria.
Lebanova H, Stoev S, Naseva E, Getova V, Wang W, Sabale U, Petrova E.
Lebanova H, et al. Among authors: petrova e.
Int J Environ Res Public Health. 2023 Feb 3;20(3):2746. doi: 10.3390/ijerph20032746.
Int J Environ Res Public Health. 2023.
PMID: 36768109
Free PMC article.
Item in Clipboard
Treatment patterns, adherence to international guidelines, and financial mechanisms of the market access of advanced breast cancer therapy in Bulgaria.
Karanyotova S, Topova B, Petrova E, Doychev P, Kapitanska E, Petrova G, Mitkova Z, Dimitrova M.
Karanyotova S, et al. Among authors: petrova e.
Front Public Health. 2023 Mar 3;11:1073733. doi: 10.3389/fpubh.2023.1073733. eCollection 2023.
Front Public Health. 2023.
PMID: 36935674
Free PMC article.
Item in Clipboard
HTA and Reimbursement Status of Metastatic Hormone‑Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer, and Metastatic Castration-Resistant Prostate Cancer Treatments in Europe: A Patient Access Landscape Review.
Bencina G, Petrova E, Sönmez D, Matos Pereira S, Dimitriadis I, Salomonsson S.
Bencina G, et al. Among authors: petrova e.
J Health Econ Outcomes Res. 2023 Jun 20;10(1):102-110. doi: 10.36469/001c.75208. eCollection 2023.
J Health Econ Outcomes Res. 2023.
PMID: 37366384
Free PMC article.
Item in Clipboard
Cite
Cite